Luye Pharma Group Ltd. (HK:2186)
:2186
Top Page
Luye Pharma Group
(2186)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$3.00
▼(-0.66% Downside)
Action:ReiteratedDate:10/18/25
Luye Pharma Group's overall stock score is primarily influenced by its strong financial performance, despite challenges in revenue and cash flow consistency. The technical analysis indicates a bearish trend, and the high P/E ratio suggests the stock may be overvalued. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Profitability / Margins
Strong gross, net, EBIT and EBITDA margins reflect efficient cost management and pricing power across product lines. Durable margins support internal funding for R&D and commercialization, provide resilience to revenue variability, and help sustain free cash generation over coming months.
Negative Factors
Revenue contraction
Negative revenue growth signals demand, access, or product mix headwinds. Continued top‑line contraction would erode operating leverage and constrain reinvestment in sales and R&D, making recovery dependent on successful new launches or regained market share over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability / Margins
Strong gross, net, EBIT and EBITDA margins reflect efficient cost management and pricing power across product lines. Durable margins support internal funding for R&D and commercialization, provide resilience to revenue variability, and help sustain free cash generation over coming months.
Read all positive factors
Luye Pharma Group (2186) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.47B
Dividend YieldN/A
Average Volume (3M)38.67M
Price to Earnings (P/E)9.8
Beta (1Y)0.86
Revenue Growth-2.54%
EPS Growth-48.74%
CountryHK
Employees5,150
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.09
Shares Outstanding3,994,515,900
10 Day Avg. Volume34,399,920
30 Day Avg. Volume38,673,367
Financial Highlights & Ratios
PEG Ratio-2.27
Price to Book (P/B)0.54
Price to Sales (P/S)1.26
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.19
Revenue Forecast (FY)HK$6.87B
Luye Pharma Group Business Overview & Revenue Model
Company Description
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida...
How the Company Makes Money
Luye Pharma Group generates revenue through multiple streams, including the sale of its proprietary pharmaceuticals and generic drugs. The company has established a robust pipeline of products that are marketed both domestically and internationall...
Luye Pharma Group Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.17B | 6.06B | 6.14B | 5.98B | 5.20B | 5.54B |
| Gross Profit | 4.12B | 4.04B | 4.20B | 4.14B | 3.40B | 3.99B |
| EBITDA | 1.73B | 1.79B | 2.08B | 1.81B | 906.88M | 1.88B |
| Net Income | 396.94M | 471.89M | 532.61M | 604.81M | -134.39M | 706.59M |
Balance Sheet | ||||||
| Total Assets | 32.03B | 29.61B | 25.49B | 24.25B | 22.58B | 20.63B |
| Cash, Cash Equivalents and Short-Term Investments | 8.83B | 6.50B | 6.11B | 5.54B | 5.51B | 5.41B |
| Total Debt | 11.87B | 10.32B | 8.42B | 9.10B | 9.49B | 9.98B |
| Total Liabilities | 15.49B | 13.86B | 11.96B | 13.21B | 13.47B | 12.53B |
| Stockholders Equity | 14.69B | 14.15B | 12.53B | 10.18B | 8.49B | 7.89B |
Cash Flow | ||||||
| Free Cash Flow | -31.91M | -1.54B | 430.23M | 490.14M | -1.36B | -486.43M |
| Operating Cash Flow | 562.16M | 167.76M | 1.60B | 1.65B | 182.37M | 1.03B |
| Investing Cash Flow | -965.94M | -1.47B | -1.42B | -1.66B | -3.44B | 138.20M |
| Financing Cash Flow | 1.98B | 2.96B | 841.60M | 54.15M | 1.88B | 253.98M |
Luye Pharma Group Technical Analysis
Positive
3.02
Price Trends
2.62
Positive
2.80
Positive
3.20
Negative
Market Momentum
<0.01
Negative
71.06
Negative
92.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2186, the sentiment is Positive. The current price of 3.02 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.62, and below the 200-day MA of 3.20, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 71.06 is Negative, neither overbought nor oversold. The STOCH value of 92.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2186.
Luye Pharma Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$111.70B | 22.87 | 11.30% | 2.70% | -18.07% | -33.27% | |
72 Outperform | HK$14.03B | 11.34 | 24.04% | 3.93% | 19.05% | 13.68% | |
64 Neutral | HK$9.37B | 20.83 | 4.47% | 4.28% | -8.49% | -9.46% | |
58 Neutral | HK$11.47B | 9.82 | 2.85% | ― | -2.54% | -48.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.16B | 22.81 | -1.84% | 0.87% | 19.21% | -115.91% |
* Healthcare Sector Average
HK:2186
Luye Pharma Group
2.92
1.08
58.70%
HK:1093
CSPC Pharmaceutical Group
9.71
5.10
110.72%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.41
0.85
153.60%
HK:1681
Consun Pharmaceutical Group Ltd.
17.07
9.04
112.68%
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.24
0.75
3.49%
Luye Pharma Group Corporate Events
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
Jan 26, 2026
Luye Pharma Group has completed the transfer of a 25% equity interest in its subsidiary Nanjing Luye from an exiting investor to NJ Xinshi, a PRC limited partnership, for a consideration of RMB1.086 billion, effective 19 January 2026. Following th...
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
Jan 26, 2026
Luye Pharma Group has announced a RMB285 million capital injection into its subsidiary Nanjing Luye by Nanjing Xinan and Ningbo Cinda, which will leave the company ultimately controlled by Shenzhen Luye with a 70.01% stake, alongside minority hold...
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
Jan 8, 2026
Luye Pharma Group has announced that China’s drug regulator has accepted a New Drug Application for a new indication of its Class 1 innovative drug Ruoxinlin (toludesvenlafaxine sustained-release tablets) to treat generalized anxiety disorde...
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
Dec 31, 2025
Luye Pharma Group has appointed independent non-executive director Ms. Xia Lian as a member of its nomination committee, effective 31 December 2025, expanding the committee to four members. The updated composition, led by chairman Professor Lo Yuk...
Luye Pharma Outlines Board Line-Up and Committee Structure
Dec 31, 2025
Luye Pharma Group Ltd. has announced the current composition of its board of directors, comprising four executive directors, two non-executive directors and five independent non-executive directors, reflecting a diversified governance structure. T...
Luye Pharma Tightens Governance With Updated Nomination Committee Mandate
Dec 31, 2025
Luye Pharma Group has updated the terms of reference for its Nomination Committee, originally adopted in 2014 and amended most recently on 31 December 2025, to refine governance around director appointments and Board composition. The revised frame...
Luye Pharma Structures RMB1.09 Billion Nanjing Luye Stake Transfer With Options and Guarantees
Dec 28, 2025
Luye Pharma Group has structured a series of transactions around the transfer of a 25% equity interest in its subsidiary Nanjing Luye for RMB1.086 billion to limited partnership NJ Xinshi, in which its unit Shandong Luye holds an approximately 33....
Luye Pharma Grants Nhwa Exclusive China Rights for Three Long-Acting Schizophrenia Drugs
Dec 24, 2025
Luye Pharma Group has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing, a subsidiary of CNS-focused specialist Jiangsu Nhwa Pharmaceutical, exclusive rights to commercialize three long-acting injectable antipsychotics—Rykindo, Ruibailai a...
Luye Pharma Completes Strategic Issuance of Exchangeable Preference Shares
Dec 12, 2025
Luye Pharma Group has completed the issuance of 1,500,000 Exchangeable Preference Shares through its wholly-owned subsidiary, Luye Geneora Holding Limited. These shares are exchangeable into existing shares of Boan Biotech, representing approximat...
Luye Pharma’s Five New Drugs Gain Inclusion in China’s 2025 Reimbursement Lists
Dec 7, 2025
Luye Pharma Group Ltd. announced the inclusion of five new products in China’s 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List, enhancing its market presence. This inclusion marks a significant milestone f...
Luye Pharma Gains FDA Approval for New CNS Drug Trials
Nov 24, 2025
Luye Pharma Group Ltd. has received FDA clearance to initiate clinical trials in the U.S. for its new drug LY03017, designed to treat Alzheimer’s disease psychosis, Parkinson’s disease psychosis, and negative symptoms of schizophrenia....
Luye Pharma Announces USD150 Million Exchangeable Shares Issuance
Nov 20, 2025
Luye Pharma Group announced the issuance of exchangeable preference shares by its wholly-owned subsidiary, which involves a subscription agreement with a third-party subscriber for USD150 million. This transaction will result in a reduction of Luy...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.